Page URL:

Success for early trial of viruses engineered to target tumours

5 September 2011
Appeared in BioNews 623

A virus that damages tumours while sparing normal healthy tissue has passed a preliminary test. JX-594, an engineered version of smallpox virus, prevented or reduced further tumour growth in 13 of 23 patients four to ten weeks after they were treated.

Patients who were injected with higher doses during the phase I clinical trial - designed to test the safety of a single injection of JX-594 - responded better. The commonest side effect was flu-like symptoms lasting a day. Only ten days after the treatment, the virus had spread in the tumours of 87 percent of patients treated with the higher dose.

'We are very excited because this is the first time in medical history that a viral therapy has been shown to consistently and selectively replicate in cancer tissue after intravenous infusion in humans', said lead researcher Dr John Bell from Ottawa Hospital Research Institute in Canada.

JX-594 is an oncolytic virus – a virus designed to preferentially infect cancer cells. The virus uses the cancer cells' machinery to produce proteins that encourage the body's immune system to target and destroy the tumour.

'Oncolytic viruses are unique because they can attack tumours in multiple ways, they have very mild side effects compared to other treatments, and they can be easily customised for different kinds of cancer', said Dr Bell. The study also provides preliminary evidence that viruses carrying foreign genes - like the one JX-594 uses to produce its targeting protein - can be delivered directly to tumours.

'Viruses that multiply in just tumour cells - avoiding healthy cells - are showing real promise as a new biological approach to target hard-to-treat cancers. But up until now they have had to be directly injected into individual tumours to avoid being immediately cleared by the immune system', said Professor Nick Lemoine of Cancer Research UK.

'This study is important because it shows that a virus previously used safely to vaccinate against smallpox in millions of people can now be modified to reach cancers through the bloodstream, even after cancer has spread widely through the patient's body'. He added: 'It is particularly encouraging that responses were seen even in tumours like mesothelioma, a cancer which can be particular hard to treat'.

Ottawa Hospital Research Institute and the University of Ottawa in partnership with Jennerex Biotherapeutics now plan to test the virus in a phase IIb trial on primary liver cancer patients. 'We are still in the early stage of testing these viruses in patients, but I believe that someday, viruses and other biological therapies could truly transform our approach for treating cancer', said Dr Bell.

The study was published in the journal Nature.

'Anti-cancer virus' shows promise
BBC |  31 August 2011
Cancer-fighting virus shown to target tumors alone
Reuters |  31 August 2011
Engineered virus 'attacks cancer cells'
NHS Choices Behind the Headlines |  09/11
Engineered virus selectively infects tumours in early trial
Cancer Research UK |  09/11
Genetic engineering breeds a cancer-fighting virus
Globe and Mail |  09/11
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Nature Letters |  09/11
Results of world-first viral therapy trial in cancer patients published in Nature
Eurekalert |  31 August 2011
8 November 2010 - by Professor Sandy Raeburn 
About 15 years ago, I formed the view we should be less ambitious about improving 'Public Understanding of Science' because we should not expect the public to understand genetic principles in detail. Better, I thought, to give a grounding in core science skills...
1 June 2010 - by Professor Marilyn Monk 
Craig Venter and colleagues recently published their work on a synthesised life form. Once again scientists are charged with playing God and the associated hype and scaremongering promise cures and treatments for all sorts of human and planetary ailments, threaten a future of unknown dangers from genetically manipulated life forms, and demand a re-analysis of the meaning of life and God....
17 January 2010 - by Sarah Pritchard 
Researchers in Switzerland have unravelled part of the mystery of dormant endogenous retroviruses (ERVs) found in our DNA which, if woken, 'multiply, induce innumerable mutations' and kill embryos at an early stage of development, as reported by the publication Scientific Computing....
3 August 2009 - by Dr Will Fletcher 
Nanoparticle delivery of a payload of toxin, straight to the tumour location, without damaging healthy cells, is as effective as chemotherapy at killing ovarian cancer in mice - but without the nasty side effects. This new method, pioneered at the Lankenau Institute for Medical Research, Pennsylvania, US, is expected to be tested in humans within 18-24 months according to a report in the journal Cancer Research....
15 March 2009 - by Adam Fletcher 
A new technique, published last week in the journal Cancer Research, has suggested an alternative approach to destroying cancer cells. Carried out in London, UK, by scientists at Cancer Research UK (CRUK), the work is the first anti-cancer therapy based on nanotechnology. Currently showing promising signs in...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.